EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast

Hope S Rugo, Joanne C Ryan

Targeted Oncology · 2026

DOI: 10.1007/s11523-026-01233-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2026. Verfasst von Hope S Rugo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. hr…. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To date, there have been no head-to-head randomized controlled trial data comparing cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in patients with HR+/HER2− metastatic breast cancer (mBC), and most prior real-world comparative effectiveness studies have been limited by short follow-up times and small patient sample sizes. In this vodcast, we provide an overview of two recent publications reporting overall survival (OS) and real-world progression-free survival (rwPFS) results from P-VERIFY, a retrospective comparative effectiveness study of CDK4/6 inhibitors plus an aromatase inhibitor (AI) among patients with HR+/HER2− mBC treated in routine clinical practice in the USA. P-VERIFY used the Flatiron Health Analytic Database to identify 9146 patients who initiated first-line (1L) treatment with palbociclib ( n = 6831), ribociclib ( n = 1279), or abemaciclib ( n = 1036), plus an AI, between February 2015 and November 2023. In primary analyses, there were no significant differences in OS and rwPFS between treatment groups after stabilized inverse probability treatment weighting, with hazard ratios ranging from 0.95 to 0.98 across pairwise group comparisons (all P > 0.05). Findings remained generally consistent across sensitivity and subgroup analyses and in a subanalysis of patients who started treatment in 2017 or later, when all three CDK4/6 inhibitors were commercially available. Taken together, results from P-VERIFY, the largest real-world study to date evaluating CDK4/6 inhibitor comparative effectiveness, suggest that there are no significant differences in OS and rwPFS between 1L palbociclib, ribociclib, and abemaciclib, plus an AI, in patients with HR+/HER2− mBC in US routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAromatase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleUnited StatesProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesBenzimidazolesNeoplasm MetastasisAminopyridinesRetrospective StudiesPurines

Substanzen

Aromatase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesribociclibProtein Kinase InhibitorsCDK4 protein, humanBenzimidazolesAminopyridinesCDK6 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. hrugo@coh.org.
  • Pfizer Inc, New York, NY, USA.

Förderung

  • Pfizer

Zitieren

APA

Rugo, H. S., & Ryan, J. C. (2026). P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast. Targeted Oncology. https://doi.org/10.1007/s11523-026-01233-0

Vancouver

Rugo HS, Ryan JC. P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast. Targeted Oncology. 2026. doi:10.1007/s11523-026-01233-0

BibTeX
@article{Rugo2026,
  author = {Rugo, Hope S and Ryan, Joanne C},
  title = {P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast},
  journal = {Targeted Oncology},
  year = {2026},
  doi = {10.1007/s11523-026-01233-0}
}
Kostenlos starten →